Vinorelbine Dosing in Adults Without Hepatic or Renal Impairment
For adults without hepatic or renal impairment, vinorelbine should be dosed at 25 mg/m² IV on days 1,8,15, and 22 of a 28-day cycle when combined with cisplatin 100 mg/m², or 30 mg/m² IV weekly when used as a single agent or with cisplatin 120 mg/m² 1.
Standard Dosing Regimens
The FDA-approved dosing varies based on whether vinorelbine is used as monotherapy or in combination:
Combination Therapy with Cisplatin
Two cisplatin dosing options exist:
Cisplatin 100 mg/m² regimen: Vinorelbine 25 mg/m² IV on days 1,8,15, and 22 of each 28-day cycle, with cisplatin 100 mg/m² given only on day 1 1
Cisplatin 120 mg/m² regimen: Vinorelbine 30 mg/m² IV once weekly, with cisplatin 120 mg/m² on days 1 and 29, then every 6 weeks 1
Single Agent Therapy
Vinorelbine 30 mg/m² IV once weekly when used as monotherapy for metastatic NSCLC 1.
Administration Details
Critical administration parameters:
- Administer as IV injection or infusion over 6 to 10 minutes 1
- Dilute to concentration between 0.5-2 mg/mL in appropriate IV solution 1
- Inject into side port of free-flowing IV line, followed by flushing with 75-125 mL of solution 1
- Must only be given intravenously - proper catheter positioning is critical before injection 1
Evidence Supporting Dosing
The guideline evidence demonstrates that cisplatin plus vinorelbine achieved an overall hazard ratio for death of 0.89 (95% CI, 0.82-0.96; P=0.005) in adjuvant therapy for completely resected NSCLC 2. The JBR.10 trial specifically used cisplatin 50 mg/m² on days 1 and 8 every 4 weeks plus vinorelbine 25 mg/m² on day 1 every 3 weeks for 16 weeks, showing median overall survival of 7.8 years versus 6.1 years with observation 2.
Key Safety Monitoring
Severe myelosuppression is the primary dose-limiting toxicity and requires vigilant monitoring 1:
- Check neutrophil counts before each dose
- Hold treatment if neutrophils <1,000 cells/mm³
- Reduce to 50% dose if neutrophils 1,000-1,499 cells/mm³
- Discontinue if three consecutive weekly doses held for neutropenia 1
Additional critical warnings:
- Risk of severe infection, septic shock, hospitalization, and death from myelosuppression 1
- Discontinue for Grade 2 or higher peripheral neuropathy 1
- Immediate management required for suspected extravasation 1
Common Pitfalls to Avoid
Do not confuse oral and IV dosing: Oral vinorelbine uses different doses (60-80 mg/m²) with approximately 40% bioavailability 3. The question specifically asks about standard dosing, which refers to IV administration per FDA labeling.
Ensure proper vascular access: Vinorelbine is a vesicant - extravasation can cause severe tissue damage. Verify catheter placement before each administration 1.
Do not skip pre-treatment counts: Neutrophil monitoring before each dose is mandatory, not optional, given the boxed warning for severe myelosuppression 1.